Standard BioTools Inc. reported a 5% revenue increase to $21.1 million in Q1 2026, driven by strong consumables sales despite a 33% drop in instrument revenue. The company reduced its operating loss by 54% and improved adjusted EBITDA loss by 78%, signaling progress toward profitability in 2026. With $524 million in cash and investments, Standard BioTools plans to pursue growth opportunities following the sale of SomaLogic. The company maintains its 2026 revenue forecast of $80-$85 million, focusing on cost savings and strategic capital deployment.
EXEED AiMOGA Robotics announced it has delivered over 2,000 robots globally, reaching more than 60 countries. This milestone highlights the company's shift from product exports to large-scale commercial deployment, with robots actively used in traffi...
The Rosen Law Firm is investigating claims that the Flow Foundation provided misleading business information to FLOW cryptocurrency investors. Investors who bought FLOW on or before December 27, 2025, and held it through December 29, 2025, may be eli...
Over five trading days from August 3 to 7, US spot Bitcoin ETFs attracted $853.5 million in net inflows, with BlackRock's iShares Bitcoin Trust (IBIT) accounting for $693 million, or 81% of the total. This inflow reversed the previous week's $61.5 mi...
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. This legal action is significant for investors as it may impact the company's governance and sto...
The JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) combines large-cap Nasdaq stocks with a covered-call strategy to provide monthly income and reduce volatility. It offers a high trailing distribution rate of about 10.9%, which increases during mar...
